Monashee Investment Management LLC Compass Therapeutics, Inc. Transaction History

Monashee Investment Management LLC

  • $774 Million
  • Q3 2024

A detailed history of Monashee Investment Management LLC transactions in Compass Therapeutics, Inc. stock. As of the latest transaction made, Monashee Investment Management LLC holds 500,000 shares of CMPX stock, worth $685,000. This represents 0.12% of its overall portfolio holdings.

Number of Shares
500,000
Previous 500,000 -0.0%
Holding current value
$685,000
Previous $500,000 84.0%
% of portfolio
0.12%
Previous 0.07%

Shares

8 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2023

Feb 12, 2024
SELL
$1.4 - $1.98 $1.02 Million - $1.44 Million
-726,142 Reduced 59.22%
500,000 $780,000
Q3 2023

Nov 13, 2023
SELL
$1.87 - $3.25 $1.39 Million - $2.42 Million
-743,154 Reduced 37.74%
1,226,142 $2.42 Million
Q2 2023

Aug 10, 2023
SELL
$2.64 - $3.48 $548,449 - $722,956
-207,746 Reduced 9.54%
1,969,296 $6.26 Million
Q1 2023

May 05, 2023
SELL
$3.14 - $5.48 $167,672 - $292,626
-53,399 Reduced 2.39%
2,177,042 $7.12 Million
Q4 2022

Feb 09, 2023
BUY
$2.55 - $5.41 $2.55 Million - $5.41 Million
1,000,000 Added 81.27%
2,230,441 $11.2 Million
Q2 2022

Aug 12, 2022
SELL
$1.43 - $3.1 $56,871 - $123,287
-39,770 Reduced 3.13%
1,230,441 $3.26 Million
Q1 2022

May 12, 2022
SELL
$1.25 - $3.5 $912,236 - $2.55 Million
-729,789 Reduced 36.49%
1,270,211 $1.74 Million
Q4 2021

Feb 07, 2022
BUY
$2.88 - $3.98 $5.76 Million - $7.96 Million
2,000,000 New
2,000,000 $6.34 Million

Others Institutions Holding CMPX

# of Institutions
79
Shares Held
91.9M
Call Options Held
0
Put Options Held
0
View Full List

About Compass Therapeutics, Inc.

CMPX Quotes by TradingView
  • Ticker CMPX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 101,285,000
  • Market Cap $139M
  • Description
  • Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases. The company's product candidates in the clinical stage of development include CTX-009, an investigational bispecific antibody that blocks Delta-like ligand 4/Notch and vascula...
More about CMPX
Track This Portfolio

Track Monashee Investment Management LLC Portfolio

Follow Monashee Investment Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Monashee Investment Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Monashee Investment Management LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email